This blog is related to the various litigations related to patents w.r.t pharma industry.
Tuesday, January 20, 2009
FDA Grants Orphan Drug Designation to ChemGenex's Omacetaxine for the Treatment of Myelodysplastic Syndromes
Jan 19, 2009 - ChemGenex Pharmaceuticals Limited announced today that the United States FDA has granted Orphan Drug designation to omacetaxine for the treatment of Myelodysplastic Syndromes (MDS).
No comments:
Post a Comment